Gunderson Dettmer client RoosterBio, a cell manufacturing platform technology company focused on sustainable regenerative medicine, has raised $15 million in Series B funding. The initial Series B round was led by Dynamk Capital and the company expects to close with additional investors later this month. The fresh funds will be used to expand and scale the RoosterBio team.

In the announcement of the funding CEO Margot Connor said, “Our investors’ show of confidence reinforces our mission to fuel the rapid commercialization of scalable regenerative cures. Through a combination of technical and business model innovation, RoosterBio is delivering on the promise of scalable bioprocess manufacturing, while growing rapidly within the enormous opportunity that is regenerative medicine. We are eager to leverage this financing to propel global and organizational growth, in partnership with Dynamk Capital and our other strategic investors.”

The Gunderson Dettmer deal team was led by John Tolpa and included Michael Deitch.